US District Judge Daniel Crabtree ruled numerous lawsuits against the marketer and manufacturer of EpiPen may proceed as a nationwide class-action under a federal racketeering statute.
‘This is heartbreaking that I work full time and literally cannot afford this medication that would save my beautiful two year old,’ one Connecticut mother wrote the Senator.
State prosecutors describe a price fixing scheme involving more than a dozen companies and as many executives responsible for sales, marketing, and pricing.